Oncimmune Holdings plc

ONC

GB00BYQ94H38

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:16 2024-04-26 am EDT			5-day change	1st Jan Change
23 ^GBX	-2.13%		-16.67%	-8.73%

Feb. 29	EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout	AN
Feb. 29	Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024	CI

Oncimmune Holdings plc Announces Change of Registered Office

June 26, 2023 at 06:11 am EDT

Oncimmune Holdings plc announced that its registered office has changed to 1 Park Row, Leeds, United Kingdom, LS1 5AB.

Latest news about Oncimmune Holdings plc

EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout	Feb. 29	AN
Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Oncimmune Holdings plc Reports Earnings Results for the Full Year Ended August 31, 2023	Feb. 29	CI
SkinBio launches food supplement on Amazon	Nov. 30	AN
Oncimmune Holdings plc Announces Board Changes	Nov. 30	CI
Oncimmune shares jump following new strategy update	23-10-12	AN
Oncimmune Holdings plc Announces Changes to the Board	23-10-12	CI
FTSE 100 Index Down 0.4% at Close, Dragged by -2-	23-08-01	DJ
UK's Oncimmune Appoints New CEO	23-08-01	MT
Oncimmune Holdings plc Announces Executive Changes	23-08-01	CI
Oncimmune Holdings plc Announces CEO Changes	23-08-01	CI
Oncimmune names chief executive successor, while finance chief leaves	23-07-12	AN
Oncimmune Appoints New CEO, Finance Director	23-07-12	MT
Oncimmune Holdings plc Announces Executive Changes	23-07-12	CI
Oncimmune Holdings plc Appoints Martin Gouldstone as CEO, Effective 1 August 2023	23-07-12	CI
Oncimmune Holdings plc Announces CFO Changes	23-07-12	CI
FTSE 100 Closes Down 0.1% Dragged by Banks	23-06-26	DJ
Oncimmune Holdings plc Announces Change of Registered Office	23-06-26	CI
FTSE 100 Closes Down 0.5% As Rate Hikes Dent Investor Confidence	23-06-23	DJ
BOE's 3Q Gilt Sales Could Fall Slightly to Around GBP9.1 Billion	23-06-23	DJ
Oncimmune Holdings shakes up leadership and unveils new growth plan	23-06-23	AN
Oncimmune Holdings CEO Steps Down; Interim Successor Named	23-06-23	MT
Oncimmune Holdings plc Announces Executive Changes	23-06-23	CI
FTSE 100 Hits Two-Month Low as Chinese Economy Raises Concerns	23-05-31	DJ
Risk of Correction in BOE Rate-Rise Bets Could Hit Sterling	23-05-31	DJ

Oncimmune Holdings plc is a United Kingdom-based immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiaries include Oncimmune Americas LLC, Oncimmune Germany GmbH, and Oncimmune LLC, among others.

Sector

Pharmaceuticals

Calendar

2024-10-30 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ONCIMMUNE HOLDINGS PLC	-8.73%	21.23M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B

Specialty & Advanced Pharmaceuticals